Enjoy complimentary customisation on priority with our Enterprise License!
The antibiotics market size is forecast to increase by USD 17.06 billion, at a CAGR of 6.07% between 2022 and 2027. Market growth hinges on multiple factors, notably the increasing incidence of infectious diseases and heightened awareness surrounding disease detection and treatment. This awareness encompasses a range of diseases, driving demand for specialized treatments and diagnostic solutions. Additionally, regulatory designations play a pivotal role, guiding market dynamics and product development. The rising prevalence of infectious diseases underscores the importance of effective healthcare interventions, spurring innovation in medical technologies and pharmaceuticals. Enhanced awareness fosters a proactive approach to disease management, leading to increased investments in research and development. Special regulatory designations further catalyze market growth, facilitating expedited approvals and market access for critical healthcare products and services. These intertwined factors create a dynamic landscape where advancements in healthcare technologies meet the evolving needs of patients and healthcare providers alike.
To learn more about this report, View Report Sample
This market report extensively covers market segmentation by product (broad-spectrum antibiotics and narrow-spectrum antibiotics), route of administration (intravenous, oral, and others), and geography (Asia, North America, Europe, and Rest of World). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
The Market encompasses a wide range of pharmaceutical products designed to combat various bacterial infections. Pathogenic bacteria, such as those causing Skin infections, Urinary tract infection, Septicemia, Gastrointestinal infection, and Respiratory infections, are the primary targets for these antibacterial drugs. Broad-spectrum antibiotics, including Cephalosporin and Penicillin, as well as Narrow-spectrum antibiotics like Macrolides, Tetracycline, Microlides, Suifonamides, Fluoroquinolones, and Aminoglycosides, play crucial roles in this market. The emergence of Multi-drug resistant bacteria and Antibiotic resistance poses significant challenges, necessitating ongoing Clinical trials to develop new antibiotics and antimicrobial resistance solutions. Key bacterial strains, such as those responsible for Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococci (VRE), continue to fuel the demand for advanced antibiotic treatments. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The rising prevalence of infectious diseases is notably driving the market growth. The global market for antibacterial drugs has experienced significant growth due to the rising incidence of bacterial infections caused by pathogenic bacteria, including multi-drug resistant strains. Antibacterial drugs play a crucial role in combating these infections. Broad-spectrum medicines, such as Cephalosporin and Penicillin, are widely used to treat various bacterial strains, including Gram-positive and Gram-negative bacteria.
However, the emergence of antibiotic resistance poses a significant challenge to the effectiveness of these drugs. Clinical trials are ongoing to develop new antibacterial drugs, such as those from GlaxoSmithKline, Merck, Melinta Therapeutics, Janssen, Biocidium Biopharmaceuticals, Blacksmith Medicines, and others. These companies are focusing on creating novel medicines to target specific bacterial strains and overcome antibiotic resistance. Therefore, such factors are estimated to drive the market during the forecast period.
Strategic alliances and mergers and acquisitions (M&A) are major trends in the market. Antibiotics play a crucial role in combating bacterial infections caused by pathogenic bacteria, including multi-drug resistant strains. The development and commercialization of antibacterial drugs, particularly broad-spectrum and narrow-spectrum medicines, require significant resources and expertise. Strategic alliances through licensing and collaboration agreements enable companies to leverage each other's technical expertise and regulatory experience.
For instance, GlaxoSmithKline and Merck have entered into co-development agreements to support their pipeline candidates. Similarly, Melinta Therapeutics, Janssen, Biocidium Biopharmaceuticals, Blacksmith Medicines, and others have formed alliances to address the challenge of antibiotic resistance. These collaborations ensure adequate funding, reduce liability costs, and attract venture investments. Such factors will help the market expansion during the forecast period.
The development of antibiotic-resistant strains is a major challenge impeding the market growth. Antibiotic market is witnessing significant growth due to the persistent threat of bacterial infections caused by pathogenic bacteria, including multi-drug resistant strains. Antibacterial drugs, such as broad-spectrum and narrow-spectrum antibiotics, are employed to combat these infections. However, the emergence of antibiotic resistance among bacterial strains poses a major challenge.
Moreover, this resistance arises due to the misuse of medicines in clinical settings and the agricultural sector. Clinical trials are ongoing to develop novel medicines against Gram positive and Gram-negative bacteria. Notable companies in this field include GlaxoSmithKline, Merck, Melinta Therapeutics, Janssen, Biocidium Biopharmaceuticals, Blacksmith Medicines, and others. These firms are dedicated to addressing antibiotic resistance through innovative solutions. This will hamper the focused market growth during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Abbott Laboratories - The company operates under multiple segments including medical devices, and nutritional products with a high focus on medical devices. The company under this segment?offers products for rhythm management, electrophysiology, heart failure, vascular, structural heart, and neuromodulation. The company's key offerings include ACITROM antibiotics.
The market report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Qualitative and quantitative market research and growth analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. In market growth analysis, data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market share growth by the broad-spectrum antibiotics segment will be significant during the forecast period. Antibacterial drugs, including broad-spectrum antibiotics, play a crucial role in combating bacterial infections caused by pathogenic bacteria. Broad-spectrum antibiotics, such as amoxicillin, levofloxacin, gatifloxacin, streptomycin, tetracycline, and chloramphenicol, offer a wide range of activities against various bacterial strains, including Gram-positive and Gram-negative bacteria.
Get a glance at the market contribution of various segments View PDF Sample
The broad-spectrum antibiotics segment shows a gradual increase in the market share of USD 31.71 billion in 2017 and continued to grow until 2021. Clinical trials are underway for various antibiotics, such as Cephalosporin, Penicillin, Macrolides, and Tetracycline, to combat antibiotic resistance. Key players in the market, such as Spero Therapeutics, Wockhardt, Bugworks Research, Pattern Bioscience, Xediton Pharmaceuticals, and RedHill Biopharma, are focusing on the development of novel antibiotics to overcome antibiotic resistance. The market is growing due to the rising prevalence of bacterial infections in the sub-economical parts of the underdeveloped and developing regions, where there is improper sanitation, a poor lifestyle of living, and improper disposal of waste, which leads to an increase in bacterial infections, thus increasing the demand for these drugs, thereby driving the market growth during the forecast period.
For more insights on the market share of various regions View PDF Sample now!
Asia is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The Market in the Asia Pacific region is projected to expand significantly during the forecast period, driven by the rising prevalence of chronic diseases and hospital-acquired infections. Key markets in this region include India and China, where the increasing elderly population is a significant factor.
Moreover, the geriatric population is more susceptible to infections due to weakened immune systems, leading to an increase in market demand. Chronic diseases such as diabetes and cancer increase the risk of infections, necessitating the use of antibiotics. Tetracyclines, Microlides, Suifonamides, Fluoroquinolones, and Aminoglycosides are commonly used antibiotics to treat various infections, including skin infections, urinary tract infections, septicemia, and gastrointestinal and respiratory infections. The route of administration for antibiotics varies, with parenteral administration being common in hospitals and retail pharmacies offering oral antibiotics for outpatient use. The market in this region is expected to grow moderately due to increasing healthcare spending and the rising burden of infectious diseases.The transformation of the regulatory landscape in Japan encourages companies to undertake strategic expansions in the country, thereby driving the market growth during the forecast period.
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2023 to 2027, as well as historical data from 2017 to 2021 for the following segments
The market is a significant sector in the healthcare industry, driven by the increasing prevalence of bacterial infections and the rising demand for effective antibiotic treatments. Antibiotics are essential medicines used to prevent and treat various bacterial infections, including respiratory, gastrointestinal, urinary tract, and skin infections. The market for antibiotics is diverse, with various types of antibiotics available, such as penicillins, cephalosporins, macrolides, fluoroquinolones, and tetracyclines. The market is also influenced by factors like the growing antibiotic resistance, the rising demand for biotic drugs, and the increasing focus on research and development of new antibiotics. Some of the prominent market players include Fedora Pharmaceuticals, Fujisawa Pharmaceutical, Helperby Therapeutics, Madam Therapeutics, Meiji Seika Pharma, MicuRx Pharmaceuticals, Selmod49, Sinovent, Global Antibiotic Research and Development Partnership, Mitsubishi Tanabe Pharma Corporation (MTPC), Biologics License Applications (BLAs), New Drug Applications (NDAs), Definitive Healthcare. The market for antibiotics is expected to grow in the coming years due to the increasing burden of bacterial infections and the need for effective treatments. The market is also witnessing the entry of several new players, offering innovative solutions to address the growing challenge of antibiotic resistance. The market for antibiotics is a dynamic and evolving sector, with continuous research and development efforts aimed at developing new and effective antibiotics to meet the growing demand.
Market Scope |
|
Report Coverage |
Details |
Page number |
163 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.07% |
Market growth 2023-2027 |
USD 17.07 billion |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
5.11 |
Regional analysis |
Asia, North America, Europe, and Rest of World (ROW) |
Performing market contribution |
Asia at 41% |
Key countries |
US, UK, China, India, and Japan |
Competitive landscape |
Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, AbbVie Inc., Armata Pharmaceuticals Inc., Aspen Pharmacare Holdings Ltd, Astellas Pharma Inc., Aurobindo Pharma Ltd., Bayer AG, F. Hoffmann La Roche Ltd., Flynn Pharma Ltd., GlaxoSmithKline Plc, Incepta Pharmaceuticals Ltd., Johnson and Johnson, Lupin Ltd., Mayne Pharma Group Ltd., Melinta Therapeutics LLC, Merck KGaA, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd. |
Market dynamics |
Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Get access to Report Sample PDF !
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Route of Administration
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.